Novavax Hauls in $666M Q1 Windfall, Boosts FY25 Outlook

Moz Farooque

Thu, May 8, 2025, 9:15 AM 2 min read

Novavax (NASDAQ:NVAX) pivots backmost to profitability aft delivering a $666.7 cardinal revenue haul successful Q1surpassing estimates by $322.8 millionand lifting its full-year gross forecast. Consequently, arsenic of 09:47:22, Novavax banal is up $0.675 (+11.34%) successful pre-market trading astatine $6.625 connected Thursday.

• Warning! GuruFocus has detected 3 Warning Signs with NVAX.

The COVID-19 vaccine shaper swung to a $519 cardinal nett income from a $148 cardinal nonaccomplishment a twelvemonth ago, fuelled by a $603 cardinal one-time summation from terminating 2 Advance Purchase Agreements and $45 cardinal successful licensing and royalty payments from Sanofiup from $4 cardinal past year.

Total expenses plunged astir 37% year-over-year to $151.4 million, with SG&A costs down astir 45% to $48 cardinal arsenic ongoing outgo cuts instrumentality hold. This crisp topline enlargement and dynamic disbursal power drove Novavax to boost its adjusted full-year gross guidance to $975 million$1.025 billion, up from $300 million$350 million, portion the Street sat adjacent $641.9 million.

Management credited the Nuvaxovid shot's dependable uptake successful cardinal markets and the lumpy timing of APG terminations for the header numbers. CFO John Trizzino noted that improved declaration presumption and disciplined spending underpinned the results, and CEO John Young highlighted renewed execution momentum arsenic the institution pivots toward broader vaccine portfolios beyond COVID.

Analysts accidental the one-off APG payment clouds underlying request trends but hold the outgo basal simplification and recurring royalty gross from partnerships similar Sanofi's should enactment sustained currency travel improvements.

Why it matters: Novavax's quality to person non-recurring gains into lasting gross streamsand to parlay outgo subject into affirmative earningswill signifier capitalist assurance arsenic the vaccine marketplace matures and contention intensifies.

Investors volition ticker Q2 income of Nuvaxovid successful emerging markets, advancement connected next-generation vaccine candidates and borderline trajectory erstwhile Novavax reports adjacent 4th results successful precocious July.

This nonfiction archetypal appeared connected GuruFocus.